Oana Maria Jigau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Oana Maria Jigau has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Andreea Iulia Papoi
Department of Gastroenterology, Faculty of Medicine, Western University “Vasile Goldiș” of Arad, Revoluţiei Boulevard 94, 310025 Arad, Romania
1 shared publication - Bogdan Miutescu
Faculty of Medicine, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania
1 shared publication - Calin Burciu
Advanced Regional Research Center in Gastroenterology and Hepatology, “Victor Babes” University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania
1 shared publication - Dana Iovanescu
Department of Gastroenterology, Faculty of Medicine, Western University “Vasile Goldiș” of Arad, Revoluţiei Boulevard 94, 310025 Arad, Romania
1 shared publication - Eftimie Miutescu
Department of Gastroenterology, Faculty of Medicine, Western University “Vasile Goldiș” of Arad, Revoluţiei Boulevard 94, 310025 Arad, Romania
1 shared publication - Eyad Gadour
Multiorgan Transplant Centre of Excellence, Liver Transplantation Unit, King Fahad Specialist Hospital, Dammam 32222, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 21 November 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (23) , 3007
Assessing Quality of Life in Hepatitis C Patients: Improvements Following Direct-Acting Antiviral Therapy—A Single-Center Romanian Study
Background/Objectives: The Hepatitis C Virus (HCV) affects both physical health and overall well-being. The advent of direct-acting antivirals (DAAs) has greatly improved treatment outcomes. This study aimed to evaluate changes in quality of life (QoL) before and after DAA therapy. Methods: Ninety-seven patients with chronic HC were assessed using the SF-36v2 Health Survey, which measures eight physical and mental health domains. The questionnaire was administered at baseline (before treatment) and 12 weeks after achieving a sustained virological response (SVR). Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated. Results: Statistically significant improvements were observed across multiple domains, including Physical Functioning (mean increase: +3.99, p < 0.001), General Health (+5.51, p < 0.001), and Vitality (+4.44, p < 0.001). Both PCS and MCS scores improved after therapy, indicating enhanced overall well-being. Subgroup analyses suggested greater physical gains among older patients and those with cirrhosis. Conclusions: Successful HCV treatment with DAAs improves not only virological outcomes but also patients’ day-to-day functioning and emotional health. Routine integration of QoL assessments is essential to capture the full spectrum of benefits offered by modern antiviral therapy.
- 21 November 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (23) , 3007
Open AccessAssessing Quality of Life in Hepatitis C Patients: Improvements Following Direct-Acting Antiviral Therapy—A Single-Center Romanian Study
Background/Objectives: The Hepatitis C Virus (HCV) affects both physical health and overall well-being. The advent of direct-acting antivirals (DAAs) has greatly improved treatment outcomes. This study aimed to evaluate changes in quality of life (QoL) before and after DAA therapy. Methods: Ninety-seven patients with chronic HC were assessed using the SF-36v2 Health Survey, which measures eight physical and mental health domains. The questionnaire was administered at baseline (before treatment) and 12 weeks after achieving a sustained virological response (SVR). Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were calculated. Results: Statistically significant improvements were observed across multiple domains, including Physical Functioning (mean increase: +3.99, p < 0.001), General Health (+5.51, p < 0.001), and Vitality (+4.44, p < 0.001). Both PCS and MCS scores improved after therapy, indicating enhanced overall well-being. Subgroup analyses suggested greater physical gains among older patients and those with cirrhosis. Conclusions: Successful HCV treatment with DAAs improves not only virological outcomes but also patients’ day-to-day functioning and emotional health. Routine integration of QoL assessments is essential to capture the full spectrum of benefits offered by modern antiviral therapy.